Cite
HARVARD Citation
Han, C. et al. (n.d.). 80P Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated overall survival results from a phase Ib/II study. Immuno-oncology technology. p. . [Online].